|
Name | Dysregulation | Biological functions in HCC | Reference |
|
HULC | Up | Promote tumor genesis, metastasis and angiogenesis; support abnormal lipid metabolism | [10–15, 45] |
|
MALAT1 | Up | Regulate arsenite-induced malignant transformation and alternative splicing of pre-mRNA, promote liver fibrosis and tumor recurrence | [17–19, 46] |
|
HOTAIR | Up | Associated with poor tumor differentiation, metastasis and early recurrence, promote migration and invasion, activate autophagy | [22, 23, 25–28] |
|
HOTTIP | Up | Associated with metastasis formation and poor survival | [47–49] |
|
MVIH | Up | Active angiogenesis, promote tumor growth and intrahepatic metastasis, inhibit cell apoptosis | [29, 30] |
|
HEIH | Up | Regulate the cell cycle, promote tumor progression | [50] |
|
PVT1 | Up | Promote cell proliferation, cell cycle, and stem cell-like properties; associated with tumor suppression | [31, 32] |
|
CCAT1 | Up | Promote proliferation and migration, function as a molecular sponge | [51] |
|
URHC | Up | Promote cell proliferation and inhibit apoptosis | [52] |
|
GIHCG | Up | Promote xenografts growth and metastasis | [53] |
|
Linc00974 | Up | Promote cell proliferation and invasion | [54] |
|
H19 | Up | Induce drug resistance, promote tumor progression and invasion | [55–57] |
Down | Suppress intrahepatic metastasis, suppress migration and invasion of HCC cells | [58, 59] |
|
MEG3 | Down | Inhibit tumor cell proliferation | [60–66] |
|
hDreh | Down | Inhibit tumor growth and metastasis | [67] |
|
LET | Down | Inhibit tumor metastasis under hypoxic conditions | [68] |
|